11 May 2016
11 May 2016
Pharmaceuticals
GlaxoSmithKline
Performance review charts
'Figure 6: Quarterly and annual Core EPS growth (CER, %)
15
10 -
5-
0
-to -
-15 - 9 9
7
I
01 2 ;
4
.5
- -g -11
Ca N NCI CV IV e)
9R2g92289Rg99 -12
el Ir O LT LS -18 • — .3 .2 4
— N Cl 0
)- )- )- )-
Li. LL LL LL
Sane 0•4.0d0 ant aneenynil• Figure 7: Pharma CER growth rates
10%
5%
, 0%
-10%
•15% 8%
2%
-1% 2%
-3% -3%
4% -3% -316 .4% -5% 4%
• 394 NCVNNnelne100000
P.R999ggq9ggq9g999
IPan Oantb, (tint Canon Ss
'Figure 8: Vaccines CER growth rates
20% t 14% 12% 10%
" 10%
10% I
a j 1%016 i 0%31 0% i
I Ial 41% -14%
18% •10%
-20% I
.30%
-40%
.50% 434_N n N N CI e) e) NI a R 0 0 VI
92M9ggq9Rgq9R299
sew* Dome. bat an pony da
'Figure 10: Adyair CER growth rates
13% 1
8% 4%5%
2% 2%2% 2% 3%
ar r e"
3% -1% 2% -2%
-17%
-22% 9%
-1%
12953F -15% 44%
-18%
Cv N ea n f) t7 e) vr V • Le Yl
PRRUM§ ,AR§§RR§P
Sane base* ark Ganasnaln
Page 8 J
'Figure 9: Consumer CER growth rates
10%
8%
8%
4%
O 2%
cc w 0%
2%
4%
6% l! 4%
4% 5% —13.411116 en$ ;ilk % 2i4
I II
2%
3%
-4%
CV CV Cl N Cl Cl ri O •LT R Lf
W9R2R9RRS9RRS9
Sown Accano ant Coroner
'Figure 1 t: New drug quarterly sales, £m
250
200
150 •I
100
50 1
I 4 158
0
3013 4013 1014
SIN icayfrourneg 2014 3014
'DB's* 4014
Nana° 1015
Sacra D_. Bank Cams,. dos 193
J
Deutsche Bank AG/London
CONFIDENTIAL — PURSUANT TO FED. R CRIM. P. 6(e)
CONFIDENTIAL SDNY_GM_00283342 DB-SDNY-0117158
EFTA01457561